Lv4
536 积分 2022-06-30 加入
Neoadjuvant Pertuzumab Biosimilar HLX11 Versus Reference Pertuzumab for Early-stage or Locally Advanced Breast Cancer: A phase 3 Equivalence Trial
10天前
已完结
Neoadjuvant Encorafenib Plus Cetuximab in BRAF -V600E–Mutated Locally Advanced Colon Cancer
16天前
已关闭
Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer
16天前
已完结
Neoadjuvant chemotherapy in locally advanced colon cancer: A systematic review with proportional meta-analysis
16天前
已完结
Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group
1个月前
已关闭
PL02.15 Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic ROS1+ NSCLC
2个月前
已关闭
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
2个月前
已完结
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
2个月前
已完结
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer
2个月前
已完结
Effectiveness and safety of PARP inhibitors in breast cancer: An umbrella review of systematic reviews and meta-analyses
2个月前
已完结
皖公网安备34019202002308
